Tumours are the groups of abnormal cells that accumulate together and form lumps and grow consistently. Tumour are categorized into noncancerous and cancerous tumours. Precancerous conditions have the potential of developing into cancer. Tumour ablation is a tool utilized to treat cancerous malignancy. Tumour ablation is the process of removing the cancerous cells from the body.
Tumour ablation became more useful during 1970s and 1980s due to advances in laparoscopic surgical approach. The most common means for definitive treatment of primary and metastatic focal malignancy, is the evolution of imaging devices during the past two decades and image-guided tumour ablation.
Tumours are the groups of abnormal cells that accumulate together and form lumps and grow consistently. Tumour are categorized into noncancerous and cancerous tumours. Precancerous conditions have the potential of developing into cancer. Tumour ablation is a tool utilized to treat cancerous malignancy. Tumour ablation is the process of removing the cancerous cells from the body.
Tumour ablation became more useful during 1970s and 1980s due to advances in laparoscopic surgical approach. The most common means for definitive treatment of primary and metastatic focal malignancy, is the evolution of imaging devices during the past two decades and image-guided tumour ablation.
The lung cancer application segment is expected to grow at the highest CAGR in the next five years due to large patient population of lung cancer present across developing and developed regions. This has increased the investment of manufacturers to develop and commercialize innovative lung cancer ablation products.
The radiofrequency ablation is widely used technique due to specificity of treating target tissue without causing damage to the surrounding cells. Microwave ablation product segment is expected to grow significantly due to increase in adoption rate of microwave ablation devices by healthcare professionals.
Region wise, the global tumour ablation market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.The global market is expected to be dominated by North America due to factors such as early introduction and adoption of rate of tumour ablation products in the region, trend of replacing older technologies and introducing the new technologies, and increase in private and public funding to develop and commercialize the novel tumour ablation products.
The Asia-Pacific market is expected to grow at a higher CAGR in the forecast period due to factors such as large population with the high prevalence of various cancers in the region, government initiatives for developing and modernizing the healthcare infrastructure.
Key players of tumour ablation devices market are Boston Scientific Corporation, St. Jude Medical, Inc., Biotronic NeuroNetwork, LLC, Baylis Medical, biolitec AG, Spectranetics, Esaote SpA, ALPINION MEDICAL SYSTEMS Co., Ltd., Chongqing Haifu Medical Technology Co., Ltd., Koninklijke Philips N.V, Hironic Co., Ltd., Monteris Medical, Inc, EDAP TMS, EYE TECH CARE, NeuWave Medical, Inc, Vison medical, AtriCure, Inc, Galil Medical Inc, ENDOCARE INC, IceCure Medical, Sanarus HealthTronics, Inc, MEDTRONIC, MedWaves, AngioDynamics, Microsulis Medical, Perseon, SympleSurgical Inc. to name a few.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global tumour ablation devices market has been classified on the basis of product type, application and end user:
On the basis of product type, the tumour ablation devices market is segmented into the following
Based on application type, the tumour ablation devices market is segmented into the following
Based on end use type, the tumour ablation devices market is segmented into the following:
The global ablation devices market is expected to reach a valuation of US$ 3.9 Bn in 2022.
The global ablation devices market grew at a healthy 9.0% CAGR between 2014 and 2021.
The increasing prevalence of cancer and the urgent need for minimally invasive treatment options are the key trends boosting the sales of ablation devices.
Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, Johnson and Johnson, AngioDynamics Inc., Biotronik SE & Co. KG., Japan Lifeline Co., CathRx Ltd., AtriCure, Inc., and Hologic, Inc. are some of the leading players present in the global ablation devices market.
The laser technology segment is anticipated to account for 10.8% of the share in the ablation devices market in 2022.
The ultrasound segment is projected to account for 15.5% of the share in the ablation devices market in the forecast period.
Explore Similar Insights
Tumour Ablation Devices Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
